Top news this week: Pfizer says third dose boosts protection, FDA approves IV selexipag
Click Here to Manage Email Alerts
This week, Pfizer says a third dose of the vaccine boosts protection, even against the delta variant; US News and World Report ranks Mayo Clinic number 1 for pulmonology and lung surgery; the FDA approves IV selexipag for adults with PAH; and more.
Read the full coverage here:
Pfizer says third dose of vaccine boosts protection, including against delta variant
CDC alters mask guidance, says even vaccinated Americans need them in some places
Mayo Clinic ranked No. 1 hospital in US for pulmonology, lung surgery
FDA approves selexipag for IV use in adults with PAH
FDA approves Saphnelo, first new lupus treatment since 2011
References:
Lupus Research Alliance press release.
Pfizer. Second quarter 2021 earnings teleconference. July 28, 2021. https://s21.q4cdn.com/317678438/files/doc_financials/2021/q2/Q2-2021-Earnings-Charts-FINAL.pdf. Accessed on July 28, 2021.
Press Conference.
Collapse
Read more about
Click Here to Manage Email Alerts
